Bavarian Nordic gets US contract to develop MVA-BN based vaccines
The five year, $17.9m contract will support the advanced development of candidate vaccine components and technologies that accelerate the immune response for use in post-event settings following the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.